Prestige Consumer Healthcare Inc
Pharmaceuticals
Prestige Consumer Healthcare Inc (PBH) Stock News
The latest PBH headlines and market coverage — 2 recent stories, updated throughout the day.
- GlobeNewswire Inc.·
Prestige Consumer Healthcare Inc. (PBH) Clear Eyes® and Pillar5 Problems Drive Stock Lower, Hagens Berman Investigating
Prestige Consumer Healthcare (PBH) shares dropped over 11% on May 14, 2026, after the company reported significant revenue declines and production problems at its recently acquired Pillar5 facility. The facility, which was supposed to resolve Clear Eyes supply chain constraints, failed to deliver expected results. Q4 2026 revenues fell 5% year-over-year, with North America OTC Eye & Ear Care declining 20.6%. Hagens Berman has opened an investigation into whether the company adequately disclosed these issues to investors.
- GlobeNewswire Inc.·
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prestige Consumer Healthcare Inc. - PBH
Pomerantz LLP is investigating potential securities fraud claims against Prestige Consumer Healthcare Inc. following the company's May 13, 2026 earnings announcement that revealed a 4.5% organic revenue decline and production issues with Clear Eyes products. The stock fell 11.35% to $45.93 per share on May 14, 2026, prompting the investigation into whether company officers and directors engaged in unlawful business practices.